Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
|Lymphoma B-cell Lymphoma Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia||Drug: Bone marrow transplantation||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas|
- Event-free survival [ Time Frame: one year ]
- Longer-term event-free survival, overall survival, relapse, nonrelapse mortality, and incidence of acute and chronic graft versus host disease [ Time Frame: day 100, 1 year, 3 years ]
- Feasibility of selecting donors based on favorable Fc receptor polymorphism status [ Time Frame: four years ]
|Study Start Date:||July 2009|
|Estimated Study Completion Date:||August 2015|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Drug: Bone marrow transplantation
Nonmyeloablative conditioning regimen: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -6 and -5. Patients undergo total body irradiation on day -1.
Allogeneic bone marrow transplantation: Patients undergo donor bone marrow infusion on day 0.
Post-transplantation therapy: Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 30, rituximab IV is administered once per week for 8 weeks.
Graft-vs-host disease prophylaxis: Beginning on day 5, patients receive oral mycophenolate mofetil until day 35 and tacrolimus (IV then changing to orally) until day 180.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00946023
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21231|
|Principal Investigator:||Yvette L Kasamon, MD||Sidney Kimmel Comprehensive Cancer Center|